Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD

Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD

<p>Abstract</p> <p>Background</p> <p>There are limited data describing patients with moderate COPD exacerbations and evaluating comparative effectiveness of maintenance treatments in this patient population. The study examined COPD patients with moderate COPD exacerbati...

Full description

Bibliographic Details
Main Authors:	Dalal Anand A, Shah Manan B, D’Souza Anna O, Lunacsek Orsolya E, Nagar Saurabh P, Crater Glenn D
Format:	Article
Language:	English
Published:	BMC 2012-05-01
Series:	Respiratory Research
Subjects:	Chronic obstructive pulmonary disease Moderate COPD exacerbations Costs Anticholinergics Fluticasone propionate-salmeterol combination
Online Access:	http://respiratory-research.com/content/13/1/41

Similar Items

A randomized trial of symptom-based management in Japanese patients with COPD
by: Betsuyaku T, et al.
Published: (2018-08-01)

Effect of combined application of tiotropium and Salmeterol and fluticasone propionate powder on disease control in stable COPD patients
by: Xiu-Ping Han, et al.
Published: (2016-06-01)

Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy
by: Moretz C, et al.
Published: (2020-10-01)

Effects of Salmeterol and Fluticasone Propionate Combination versus Fluticasone Propionate on Airway Function and Eosinophilic Inflammation in Mild Asthma
by: Makoto Hoshino, et al.
Published: (2009-01-01)

The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study
by: Jones R, et al.
Published: (2017-08-01)

Step-down therapy in well-controlled asthmatic patients using salmeterol xinafoate/fluticasone propionate combination therapy
by: Horiuchi K, et al.
Published: (2016-03-01)

Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids
by: Tsan-Ming Huang, et al.
Published: (2020-09-01)

Optimal step-down approach for pediatric asthma controlled by salmeterol/fluticasone: A randomized, controlled trial (OSCAR study)
by: Kenichi Akashi, et al.
Published: (2016-07-01)

Relationship between the anti-inflammatory properties of salmeterol/fluticasone and the expression of CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+ </sup>regulatory T cells in COPD
by: Yang Li, et al.
Published: (2011-10-01)

In vitro aerodynamic analysis of co-spray dried fluticasone propionate (FP) and salmeterol xinafoate (SX) dry powder inhalation aerosols with lactose-alternative excipient
by: Malapit, Monica, et al.
Published: (2017)

The comparison of fluticasone propionate/formoterol with fluticasone propionate/salmeterol for paediatric asthma: a meta-analysis of randomized controlled trials
by: Xiaofen Jin, et al.
Published: (2020-01-01)

Effect of tiotropium bromide combined with salmeterol fluticasone inhalation on airway function and airway inflammation in patients with moderate-severe stable COPD
by: Min Xiang
Published: (2016-12-01)

Comparison of fluticasone propionate and budesonide on COPD macrophage and neutrophil function
by: Belchamber KBR, et al.
Published: (2018-09-01)

Fluticasone propionate and increased risk of pneumonia in COPD: is it PAFR-dependent?
by: Sohal SS
Published: (2017-12-01)

Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus as-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in patients Without Optimally Controlled asthma (REACT) Study [Corrigendum]
by: Cheng SL, et al.
Published: (2021-02-01)

Budesonide/Formoterol Anti-Inflammatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus As-Needed, Short-Acting β2 Agonist: Real-World Effectiveness in pAtients without Optimally Controlled asThma (REACT) Study
by: Cheng SL, et al.
Published: (2020-12-01)

Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma
by: Bernstein David I, et al.
Published: (2011-12-01)

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial
by: Donald P. Tashkin, et al.
Published: (2018-10-01)

Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial
by: Papi Alberto, et al.
Published: (2012-06-01)

In Vitro Performance of the Wixela Inhub Inhaler Using Severe Chronic Obstructive Pulmonary Disease Patient Inhalation Profiles
by: Cooper, A., et al.
Published: (2022)

Real-life effectiveness of indacaterol–glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study
by: Kaplan A, et al.
Published: (2019-01-01)

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
by: Antonio R. Anzueto, et al.
Published: (2018-06-01)

Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study
by: Jean Bousquet, et al.
Published: (2017-04-01)

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting
by: Perrone V, et al.
Published: (2016-11-01)

Microencapsulation of Fluticasone Propionate and Salmeterol Xinafoate in Modified Chitosan Microparticles for Release Optimization
by: Nina Maria Ainali, et al.
Published: (2020-08-01)

The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population
by: Kato M, et al.
Published: (2019-12-01)

Determinants of exacerbation risk in patients with COPD in the TIOSPIR study
by: Calverley PMA, et al.
Published: (2017-11-01)

Effects of Salmeterol Xinafoate and Fluticasone Propionate on Immunological Activation of Human Cultured Mast Cells
by: Hirotomo Akabane, et al.
Published: (2006-01-01)

Impact of antibiotics on acute exacerbations of COPD
by: Wafaa Ali Hassan, et al.
Published: (2015-07-01)

Prompt initiation of maintenance treatment following a COPD exacerbation: outcomes in a large insured population
by: Coutinho AD, et al.
Published: (2016-06-01)

Exacerbations of COPD
by: Pavord ID, et al.
Published: (2016-02-01)

Hospitalization due to exacerbation of COPD: "Real-life" outcomes
by: Lilia Azzi Collet da Rocha Camargo, et al.

COPD exacerbation: factors influencing hospitalization duration
by: Gashynova K.Yu.
Published: (2015-03-01)

COPD exacerbation: factors influencing hospitalization duration.
by: K. Yu. Gashynova
Published: (2015-03-01)

Information Needs in COPD After an Educational Programme: Influence in Exacerbations and Admissions
by: Amado CA, et al.
Published: (2020-10-01)

No association between exacerbation frequency and stroke in patients with COPD
by: Windsor C, et al.
Published: (2016-02-01)

Consolidation and Exacerbation of COPD
by: John R. Hurst
Published: (2018-06-01)

INFLUENCE OF BRONCHOLYTIC THERAPY ON VENTRICULAR RHYTHM DISORDERS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
by: Kh. Kh. Shugushev, et al.
Published: (2016-01-01)

The usefulness of soluble receptor for advanced glycation end-products in the identification of COPD frequent exacerbator phenotype
by: Miłkowska-Dymanowska J, et al.
Published: (2018-11-01)

Colds as predictors of the onset and severity of COPD exacerbations
by: Johnston NW, et al.
Published: (2017-03-01)